Home ›
NPI 1255454712
1255454712
1255454712 was paid $82K by Medicaid between Jan 2018 and Sep 2022, across 36 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 60% of everything it billed.
33Billing provider info1255454712
33aNPI1255454712
33bProvider type—
28Total paid$82K
24GClaims29,690
24DCodes billed36
24AFirst – last monthJan 2018 – Sep 2022
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,319 | $18.00 | |
| 2019 | 6,004 | $508.09 | |
| 2020 | 6,888 | $7K | |
| 2021 | 8,045 | $45K | |
| 2022 | 5,434 | $29K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 60% | 1,207 | 937 | $50K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 17% | 666 | 518 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 10% | 888 | 59 | $8K |
| 80053 | Comprehensive metabolic panel | 2.6% | 3,043 | 2,073 | $2K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.7% | 138 | 55 | $1K |
| 87529 | 1.3% | 113 | 58 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,022 | 648 | $755.87 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 4,384 | 2,627 | $506.29 |
| 87481 | <1% | 73 | 42 | $442.26 | |
| 87653 | <1% | 95 | 53 | $425.16 | |
| 87641 | <1% | 97 | 56 | $425.16 | |
| 87496 | <1% | 94 | 55 | $421.20 |
24 more codes
| 87640 | <1% | 92 | $401.54 | |
| 87532 | <1% | 96 | $397.80 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,012 | $375.00 |
| 82607 | <1% | 1,704 | $329.85 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,323 | $309.85 |
| 80050 | General health panel | <1% | 28 | $241.12 |
| 80061 | Lipid panel | <1% | 916 | $195.13 |
| 87511 | <1% | 34 | $187.20 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 945 | $159.80 |
| 87186 | <1% | 101 | $103.35 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,502 | $96.93 |
| 87150 | <1% | 116 | $69.18 | |
| 81001 | <1% | 402 | $63.14 | |
| 82044 | <1% | 378 | $56.14 | |
| 87088 | <1% | 324 | $44.06 | |
| 83735 | <1% | 38 | $41.55 | |
| 84439 | <1% | 1,075 | $19.03 | |
| 82570 | 0% | 392 | $0.00 | |
| 83880 | 0% | 20 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 4,134 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 56 | $0.00 |
| 82746 | 0% | 40 | $0.00 | |
| 87500 | 0% | 106 | $0.00 | |
| 87077 | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.